AzTrials
AzTrials

Arthritis, RheumatoidPhase 3ORAL1069NCT01039688

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

A Phase 3 study testing CP-690,550 and Disease-modifying antirheumatic drug in people with Arthritis, Rheumatoid, run by Pfizer at 176 sites in 30 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Arthritis, Rheumatoid
What is being tested?
CP-690,550 and Disease-modifying antirheumatic drug
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
956 participants
Where
176 sitesin 30 countries
Study dates
Jan 2010to Mar 2013
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults with moderate to severe RA (Rheumatoid Arthritis) who have not been treated with methotrexate.
  • Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.
  • Active disease as defined by both >=6 tender or painful joints on motion and >= 6 joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a C-reactive protein (CRP) concentration > 7 mg/dL

Who cannot join

  • Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L
  • History of any other rheumatic autoimmune disease other than Sjogren's syndrome
  • No malignancy or history of malignancy
  • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
  • No chronic liver disease, recent or active hepatitis or other contraindication to methotrexate therapy

Trial locations and contacts

176 sites in 30 countries.

176 sites in 30 countries

United States41 sites
  • The Center for Rheumatology

    Albany, New York, 12206

  • Austin Rheumatology Research

    Austin, Texas, 78705

  • Medical University of South Carolina - Rheumatology

    Charleston, South Carolina, 29425

  • Medical University of South Carolina Investigational Drug Services

    Charleston, South Carolina, 29425

  • Medical University of South Carolina

    Charleston, South Carolina, 29425

  • Mountain State Clinical Research

    Clarksburg, West Virginia, 26301

  • United Hospital Center (Imaging Only)

    Clarksburg, West Virginia, 26301

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • Medical Associates Clinic, PC

    Dubuque, Iowa, 52002

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • University of North Texas Health Science Center at Fort Worth

    Fort Worth, Texas, 76107

  • Southeastern Arthritis Center

    Gainesville, Florida, 32607

  • Southeastern Imaging and Diagnostics

    Gainesville, Florida, 32607

  • Southeastern Integrated Medical, PL dba Florida Medical Research

    Gainesville, Florida, 32607

  • PMG Research of Hickory, LLC

    Hickory, North Carolina, 28601

  • PMG Research of Hickory, LLC

    Hickory, North Carolina, 28602

  • Diagnostic Rheumatology and Research, PC

    Indianapolis, Indiana, 46227

  • Arthritis Clinic

    Jackson, Tennessee, 38305

  • West Tennessee Research Institute

    Jackson, Tennessee, 38305

  • University of California San Diego Perlman Ambulatory Clinic

    La Jolla, California, 92037-0943

  • University of California San Diego Center for Innovative Therapy

    La Jolla, California, 92093 0943

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516

  • Little Rock Diagnostic Clinic

    Little Rock, Arkansas, 72205

  • Keck Hospital of USC, Lower Level Pharmacy

    Los Angeles, California, 90033

  • Keck Hospital of USC

    Los Angeles, California, 90033

  • USC Keck School of Medicine

    Los Angeles, California, 90033

  • University of California Los Angeles (UCLA)

    Los Angeles, California, 90095

  • Center for Arthritis and Rheumatic Diseases

    Miami, Florida, 33173

  • Louisiana State University Health Sciences

    New Orleans, Louisiana, 70115

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma, 73112

  • AAIR Research Center

    Rochester, New York, 14618

  • Sarasota Arthritis Research Center

    Sarasota, Florida, 34239

  • Investigational Drug Service

    Seattle, Washington, 98101

  • Virginia Mason Medical Center

    Seattle, Washington, 98101

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida, 33321

  • Bernard F. Germain, MD

    Tampa, Florida, 33613

  • Burnette & Silverfield, MDS PLC

    Tampa, Florida, 33614

  • Catalina Pointe Clinical Research, Inc.

    Tucson, Arizona, 85704

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

  • Clinical Research Center of Reading, LLP

    Wyomissing, Pennsylvania, 19610

Other trials in United States

Russia14 sites
  • State Healthcare Institution Regional Clinical Hospital

    Barnaul, 656024

  • State Healthcare Institution Regional Clinical Hospital for War Veterans

    Kemerovo, 650099

  • Federal State Institution named after Academician E.N. Meshalkin, Novosibirsk State Research

    Novosibirsk, 630055

  • Scientific Research Institute of Clinical and Experimental Lymphology of the Siberian Branch of RAMS

    Novosibirsk, 630117

  • State Health Institution City Hospital # 25, City Rheumatology Center of St. Petersburg

    Saint Petersburg, 190068

  • Clinical Hospital #122 named after L.G. Sokolov of the Federal Medical-Biological Agency

    Saint Petersburg, 194291

  • Almazov Federal Heart, Blood and Endocrinology Centre

    Saint Petersburg, 197341

  • State Healthcare Institution City Hospital # 40 of Administrative Health Resort District

    Saint Petersburg, 197706

  • St. Petersburg State Institution of Healthcare Consultative-diagnostic Center #85

    Saint Petersburg, 198260

  • Smolensk State Medical Academy, Clinical Research Centre of Diagnostic Medicine and Drugs

    Smolensk, 214019

  • Regional State Healthcare Institution of Tomsk Regional Clinical Hospital

    Tomsk, 634063

  • State Healthcare Institution

    Yekaterinburg, 620102

  • Ltd. Medical Association "Novaya Bolnitsa" (X-Ray Only)

    Yekaterinburg, 620109

  • State Educational Institution of Higher Professional Education

    Yekaterinburg, 620149

Other trials in Russia

Canada12 sites
  • Burlington Rheumatology and Osteoporosis Clinic

    Burlington, Ontario, L7L 0B7

  • Rheumatology Research Associates Ltd.

    Edmonton, Alberta, T5M 0H4

  • Dr. William G. Bensen Medicine Professional Corporation

    Hamilton, Ontario, L8N 1Y2

  • Office of Dr. Fernando Bianchi

    Hamilton, Ontario, L8N 1Y2

  • MAC Research Inc.

    Hamilton, Ontario, L8N 2B6

  • KW Musculoskeletal Research Inc.

    Kitchener, Ontario, N2M 5N6

  • Rheumatology Research Associates

    Ottawa, Ontario, K1H 1A2

  • Niagara Peninsula Arthritis Centre

    St. Catharines, Ontario, L2N 7E4

  • PerCuro Clinical Research Ltd.

    Victoria, British Columbia, V8V 3P9

  • Windsor Radiological Associates

    Windsor, Ontario, N8X 1K7

  • Clinical Research and Arthritis Centre

    Windsor, Ontario, N8X 5A6

  • Manitoba Clinic

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

Germany8 sites
  • Privat-Praxis, Rheumatologie (P515)

    Aachen, 52064

  • Schlosspark-Klinik

    Berlin, 14059

  • Studienambulanz, Medizinische Klinik 3 Universitaetsklinikum Erlangen

    Erlangen, 91054

  • Schwerpunktpraxis Rheumatologie FAE Innere Medizin

    Halle, 06108

  • Schoen Klinik Hamburg-Eilbek, Abt. Rheumatologie und Klin. Immunologie

    Hamburg, 22081

  • Arztpraxis, Internist - Rheumatologie

    Nuremberg, 90429

  • Rheumaforschung - Studienambulanz Dr. Wassenberg

    Ratingen, 40882

  • Schwerpunktpraxis fuer Rheumatologie

    Rheine, 48431

Other trials in Germany

India7 sites
  • Rheumatic Disease Clinic

    Ahmedabad, Gujarat, 380009

  • Shalby Hospital

    Ahmedabad, 380015

  • Shirdi Sai Hospital

    Bangalore, Karnataka, 560 054

  • Mahavir Hospital & Research Center

    Hyderabad, Andhra Pradesh, 500 004

  • Arthritis Research and Care Foundation

    Pune, Maharashtra, 411 001

  • Jehangir Clinical Development Centre Pvt. Ltd.

    Pune, Maharashtra, 411 001

  • Department of Rheumatology

    Secunderabad, Andhra Pradesh, 500003

Other trials in India

Brazil6 sites
  • Centro de Estudos em Terapias Inovadoras

    Curitiba, Paraná, 80060-240

  • CIP - Centro Internacional de Pesquisas

    Goiânia, Goiás, 74110-120

  • Clinica de Raios X Nabyh Salum S/S - Clinica Sao Matheus

    Goiânia, Goiás, 74115-030

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Rio Grande do Sul, 90610-000

  • CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda

    Rio de Janeiro, 22271-100

  • CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda

    São Paulo, São Paulo, 04266-010

Other trials in Brazil

Bulgaria6 sites
  • Revmatologichno Otdelenie, MBAL - Plovdiv

    Plovdiv, 4000

  • MBAL-Ruse, AD, IV Terapevtichno i kardiologichno otdelenie

    Rousse, 7002

  • MBAL na Voennomeditsinska Akademia - Sofia, Klinika po Revmatologia i Kardiologia

    Sofia, 1606

  • MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia

    Sofia, 1612

  • DKTs "Sveta Anna", Sofia; Konsultativen kabinet po Revmatologia

    Sofia, 1709

  • MOBAL "D-r Stefan Cherkezov" AD, Revmokardiologichno otdelenie s intenziven sektor

    Veliko Tarnovo, 5000

Other trials in Bulgaria

Czechia6 sites
  • Fakultni nemocnice Brno

    Brno, 62500

  • Revmacentrum MUDr. Mostera, s.r.o.

    Brno-Židenice, 61500

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, 50005

  • Revmatologicka ambulance

    Ostrava-Poruba, 70800

  • Revmatologicky ustav

    Prague, 128 50

  • Revmatologicka ambulance

    Prague, 140 00

Other trials in Czechia

Ukraine6 sites
  • State Institution "Republican Clinical Hospital of the Ministry of Health of Ukraine"

    Kyiv, 04053

  • State Institution "Republican Clinical Hospital of the Ministry of Health of Ukraine"

    Kyiv, 04114

  • Municipal City Clinical Hospital #4, Department of Rheumatology

    Lviv, 79011

  • Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology

    Odesa, 65026

  • CRI "Clinical Territorial Medical Association "University Clinic", Department of Rheumatology

    Simferopol, Autonomous Republic of Crimea, 95017

  • Vinnitsa Regional Clinical Hospital n.a. M.I. Pirogov

    Vinnitsa, 21018

Other trials in Ukraine

Chile5 sites
  • Hospital Regional de Rancagua

    Rancagua, 2841959

  • Centro de Estudios Reumatologicos

    Santiago, RM, 7501126

  • Consulta Privada Dra. Marta Aliste

    Santiago, RM, 7510186

  • Consulta Privada Dra. Lucia Ponce

    Temuco, Araucania, 4790928

  • Estudios Clinicos V Region

    Viña del Mar, Valparaiso, 2570017

Other trials in Chile

Hungary5 sites
  • Drug Research Center Kft. Reumatologiai Szakrendeles

    Balatonfüred, 8230

  • Revita Reumatologiai Rendelo

    Budapest, 1027

  • Synexus Magyarorszag Kft.

    Budapest, H-1036

  • Mozgasszervi Rehabilitacios Kozpont, Reumatologiai szakrendeles

    Mezőkövesd, 3400

  • MAV Korhaz es Rendelointezet

    Szolnok, H-5000

Other trials in Hungary

Poland5 sites
  • Przychodnia Medyczna Lekarskiej Spoldzielni Pracy

    Gdynia, 81-367

  • Centrum Leczenia Chorob Cywilizacyjnych Sp. z.o.o. SKA Oddzial Gdynia

    Gdynia, 81-384

  • Centrum Leczenia Chorob Cywilizacyjnych Sp. z o.o. SKA Oddzial Katowice

    Katowice, 40-748

  • Synexus SCM Sp. z o.o. Oddzial Warszawa

    Warsaw, 01-192

  • Rheuma Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy

    Warsaw, 02-118

Other trials in Poland

Slovakia5 sites
  • Reumatolog s.r.o.

    Bratislava, 81108

  • AAGS, s.r.o. , nestatne zdravotnicke zariadenie

    Dunajská Streda, 92901

  • Reumatologicka ambulancia, Ecclesia, s.r.o.

    Nové Zámky, 94001

  • Narodny ustav reumatickych chorob

    Piešťany, 921 12

  • Nestatna reumatologicka ambulancia

    Žilina, 010 01

Other trials in Slovakia

Spain5 sites
  • Hospital de Basurto

    Bilbao, Vizcaya, 48013

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28007

  • Hospital Civil. Hospital Regional Universitario Carlos Haya

    Málaga, 29009

  • Hospital Nuestra Señora de La Esperanza

    Santiago de Compostela, A Coruña, 15705

  • Hospital Universitario Virgen Macarena

    Seville, 41009

Other trials in Spain

Mexico4 sites
  • Instituto Jaliscience de Investigación Clínica SA de CV

    Guadalajara, Jalisco, 44158

  • Unidad de Investigacion en Enfermedades Cronico Degenerativas

    Guadalajara, Jalisco, 44620

  • Hospital Universitario Jose Eleuterio Gonzalez

    Monterrey, Nuevo León, 64020

  • Unidad de Enfermedades Reumaticas y Cronico Degenerativas SC

    Torreón, Coahuila, 27000

Other trials in Mexico

New Zealand4 sites
  • The Canterbury Geriatric Medical Research Trust, c/- The Princess Margaret Hospital

    Christchurch, 8022

  • Ryburns Building, Waikato Hospital

    Hamilton, 3204

  • Centre for Clinical Research and Effective Practice (CCREP Middlemore Hospital

    Otahuhu, Auckland, 1640

  • Timaru Hospital, Clinical Trials Unit

    Timaru, 7910

Other trials in New Zealand

Peru4 sites
  • Hospital Nacional IV Alberto Sabogal Sologuren

    Callao, C-02

  • Clinica Anglo Americana

    Lima, L 27

  • Centro Medico Corpac

    Lima, L-27

  • Instituto Peruano del Hueso y la Articulacion SAC-Privado-Lima/Centro de Investigacion IPHAR

    Lima, L-27

Other trials in Peru

Argentina3 sites
  • OMI - Organización Médica de Investigación

    Buenos Aires, C1015ABO

  • Saint Dennis Medical Group S.A.

    Buenos Aires, C1034ACO

  • Consultorios Reumatológicos Pampa

    Buenos Aires, C1428DZF

Other trials in Argentina

Australia3 sites
  • Emeritus Research

    Malvern East, Victoria, 3145

  • Rheumatology Research Unit Sunshine Coast

    Maroochydore, Queensland, 4558

  • The Queen Elizabeth Hospital, Department of Rheumatology

    Woodville, South Australia, 5011

Other trials in Australia

Colombia3 sites
  • Centro de Reumatologia y Ortopedia

    Barranquilla, Atlántico

  • Centro Integral de Reumatologia e Inmunologia CIREI

    Bogota, Cundinamarca, 0000

  • Servimed E.U

    Bucaramanga, Santander Department

Other trials in Colombia

Malaysia3 sites
  • Sarawak General Hospital

    Kuching, 93586

  • Sunway Medical Centre

    Petaling Jaya, Selangor, 46150

  • Hospital Tuanku Ja'afar

    Seremban, Negeri Sembilan, 70300

Other trials in Malaysia

Philippines3 sites
  • Chong Hua Hospital

    Cebu City, 6000

  • Brokenshire Integrated Health Ministries, Inc. Brokenshire Memorial Hospital

    Davao City, 8000

  • Rayuma Klinik, OPD Department, Jose R. Reyes Memorial Medical Center

    Manila, 1003

Other trials in Philippines

South Korea3 sites
  • Seoul National University Hospital, Rheumatology, Internal Medicine

    Seoul, 110-744

  • Yonsei University College of Medicine, Severance Hospital, Rheumatology, Internal Medicine

    Seoul, 120-752

  • Asan Medical Center, Rheumatology, Internal Medicine

    Seoul, 138-736

Other trials in South Korea

Sweden3 sites
  • Skanes Universitetssjukhus i Malmo

    Malmö, 205 02

  • Sundsvalls sjukhus- Medicinkliniken

    Sundsvall, 851 86

  • Akademiska sjukhuset, Reumatologmottagningen

    Uppsala, 751 85

Other trials in Sweden

Taiwan3 sites
  • Chung-Ho Memorial Hospital, Kaohsiung Medical University

    Kaohsiung City, 807

  • Taichung Veterans General Hospital

    Taichung, 407

  • National Cheng Kung University Hospital

    Tainan, 704

Other trials in Taiwan

Thailand3 sites
  • Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital

    Bangkok, 10400

  • Siriraj Hospital, Mahidol University

    Bangkok, 10700

  • Rheumatology Unit, Department of Internal Medicine, Phramongkutklao Hospital

    Phayathai, Bangkok, 10400

Other trials in Thailand

Costa Rica2 sites
  • Centro de Reumatología y Osteoporosis, Cartago

    Cartago, 00000

  • Hospital Cima San Jose

    San José, 00000

Other trials in Costa Rica

Puerto Rico2 sites
  • Ponce School of Medicine

    Ponce, 00716

  • Edificio Parra

    Ponce, 00717-1321

Other trials in Puerto Rico

Belgium1 site
  • Universitair Ziekenhuis Gent - Reumatologie

    Ghent, 9000

Other trials in Belgium

Dominican Republic1 site
  • Patricia Alvarez Site

    Santo Domingo, 00000

Other trials in Dominican Republic

About this study

Official title: Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis

This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.

Being tested
CP-690,550, Disease-modifying antirheumatic drug
Keywords
oral JAK inhibitor, MTX, DMARD, clinical trial, joint diseases, autoimmune diseases, anti-Inflammatory agents, rheumatic diseases
Medical subject headings
Arthritis, Rheumatoid, Joint Diseases, Autoimmune Diseases, Rheumatic Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CP-690,550Drug

    Oral tablets administered at a dose of 5 mg BID for 24 months

  • CP-690,550Drug

    Oral tablets administered at a dose of 10 mg BID for 24 months

  • Disease-modifying antirheumatic drugDrug

    Also called DMARD, MTX

    Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months

Study groups in NCT01039688
Study groupRoleWhat they receive
5 mg BID CP-690,550ExperimentalNot described
Receives: Drug: CP-690,550
10 mg BID CP-690,550ExperimentalNot described
Receives: Drug: CP-690,550
methotrexateActive comparatorNot described
Receives: Drug: Disease-modifying antirheumatic drug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Modified Total Sharp Score (mTSS) at Month 6

    mTSS: sum of erosion and joint space narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score).

    Measured: Month 6

  2. Change From Baseline at Month 6 in mTSS

    mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represents improvement.

    Measured: Month 6

  3. Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response at Month 6

    ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender joints count (TJC) or swollen joints count (SJC) and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of the Health Assessment Questionnaire [HAQ]), and 5) C-reactive protein (CRP).

    Measured: Month 6

  4. Absolute Blood Pressure (BP) Values (mmHg)

    BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, and 24

  5. Change From Baseline in BP Values (mmHg)

    BP: pressure exerted by the blood upon the walls of the blood vessels and especially arteries, usually measured on the radial artery using a sphygmomanometer. Systolic BP: the highest arterial blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle of the heart. Diastolic BP: the lowest arterial blood pressure of a cardiac cycle occurring during diastole of the heart.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, and 24

Secondary outcomes (83)
  1. mTSS Score at Baseline, Months 12 and 24

    mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score).

    Measured: Baseline, Months 12 and 24

  2. Change From Baseline in mTSS Score at Months 12 and 24

    mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represents improvement.

    Measured: Months 12 and 24

  3. Percentage of Participants With no Progression in mTSS at Months 6, 12, and 24

    mTSS: sum of erosion and JSN scores for 44 joints (16 per hand and 6 per foot). mTSS scores range from 0 (normal) to 448 (worst possible total score). A increase of less than or equal to (≤)0.5 in mTSS is considered to be no progression in the mTSS.

    Measured: Months 6, 12, and 24

  4. Percentage of Participants With no Worsening in Erosion Score (Increase ≤0.5) at Months 6, 12, and 24

    Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280. An increase of ≤0.5 in Erosion Score is considered to be 'no worsening' in the Erosion Score.

    Measured: Months 6, 12, and 24

  5. Erosion Scores

    Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280.

    Measured: Baseline, Months 6, 12, and 24

  6. JSN Scores

    JSN score: severity of JSN in 42 joints (15 per hand and 6 per foot), including subluxation, scored from 0 (no/normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation). Maximum JSN score was 168.

    Measured: Baseline, Months 6, 12, and 24

  7. Change From Baseline in Erosion Scores

    Joint erosion score: erosion severity in 44 joints (16 per hand, 6 per foot). Each joint scored according to surface area involved, from 0 (no erosion) to 5 (extensive bone loss from more than one half of articulating bone). Because each side of foot joint was graded, maximum erosion score for foot joint was 10. Thus, maximum erosion score was 280. Change = score at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Measured: Months 6, 12, and 24

  8. Change From Baseline in JSN Scores

    JSN score: severity of JSN in 42 joints (15 per hand and 6 per foot), including subluxation, scored from 0 (no/normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation). Maximum JSN score was 168. Change = scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.

    Measured: Months 6, 12, and 24

  9. Percentage of Participants Achieving an ACR70 Response

    ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 1, 2, 3, 9, 12, 15, 18, 21, and 24

  10. Percentage of Participants Achieving an ACR20 Response

    ACR20 response: ≥20% improvement in TJC or SJC and ≥20% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  11. Percentage of Participants Achieving an ACR50 Response

    ACR50 response: ≥50% improvement in TJC or SJC and ≥50% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  12. Tender Joints Count (TJC)

    Sixty-eight (68) joints were assessed by a blinded joint assessor to determine the number of joints considered tender or painful. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 68 joints to be assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V); lower extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  13. Change From Baseline in TJC

    Sixty-eight (68) joints were assessed by a blinded joint assessor to determine the number of joints considered tender or painful. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 68 joints to be assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  14. Swollen Joints Count (SJC)

    Sixty-six (66) joints were assessed by a blinded joint assessor for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 66 joints assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  15. Change From Baseline in SJC

    Sixty-six (66) joints were assessed by a blinded joint assessor for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Artificial joints were not assessed. 66 joints assessed were: upper body (temporomandibular, sternoclavicular, acromioclavicular); upper extremity: shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as one unit), MCP (I, II, III, IV, V), thumb IP, PIP (II, III, IV, V), DIP (II, III, IV, V); lower extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), MTP (I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  16. Patient Assessment of Arthritis Pain

    Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm=no pain and 100 mm=most severe pain.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  17. Change From Baseline in Patient Assessment of Arthritis Pain

    Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm=no pain and 100 mm=most severe pain.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  18. Physician Global Assessment of Arthritis

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm=very good and 100 mm=very bad.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  19. Change From Baseline in Physician Global Assessment of Arthritis

    Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm=very good and 100 mm=very bad.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  20. Patient Global Assessment of Arthritis

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  21. Change From Baseline in Patient Global Assessment of Arthritis

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0=very well and 100=very poorly.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  22. C-Reactive Protein

    CRP measured in milligrams per liter (mg/L)

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  23. Change From Baseline in CRP

    Change from Baseline in CRP measured in mg/L.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  24. Disease Activity Score Based on 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3) CRP

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) less than or equal to (≤)3.2 implied low disease activity, greater than (>)3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) less than (<)2.6 = remission.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  25. Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeter/hour [mm/hour]) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  26. Change From Baseline in DAS28-3(CRP)

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  27. Change From Baseline in DAS28-4(ESR)

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  28. Percentage of Participants With DAS28-3(CRP) ≤3.2

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  29. Percentage of Participants With DAS28-4(ESR) ≤3.2

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  30. Percentage of Participants With DAS28-3(CRP) <2.6

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  31. Percentage of Participants With DAS28-4(ESR) <2.6

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  32. Percentage of Participants With DAS28-3(CRP) Response (Good or Moderate Improvement)

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28 categorical responses define a good (absolute: <3.2 or >1.2 improvement from baseline [BL]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: >5.1 or <0.6 change from BL).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  33. Percentage of Participants With DAS28-4(ESR) Response (Good or Moderate Improvement)

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28 categorical responses define a good (absolute: <3.2 or >1.2 improvement from BL), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: >5.1 or <0.6 change from BL).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  34. Percentage of Participants With an ACR70 Response Sustained at Least 6 Months

    ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 6, 9, 12, 15, 18, 21, and 24

  35. Percentage of Participants With Consecutive Visits of ACR20 Response by Number of Consecutive Visits

    ACR20 response: ≥20% improvement in TJC or SJC and ≥20% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24

  36. Percentage of Participants With Consecutive Visits of ACR50 Response by Number of Consecutive Visits

    ACR50 response: ≥50% improvement in TJC or SJC and ≥50% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24

  37. Percentage of Participants With Consecutive Visits of ACR70 Response by Number of Consecutive Visits

    ACR70 response: ≥70% improvement in TJC or SJC and ≥70% improvement in at least 3 of 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability (disability index of HAQ), and 5) CRP.

    Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24

  38. Percentage of Participants With Consecutive Visits of DAS28-3(CRP) <2.6 by Number of Consecutive Visits

    DAS28-3(CRP) was calculated from the SJC and TJC using 28-joints count and CRP (mg/L). Total score range: 0 to approximately 10, higher score indicated more disease activity. DAS28-3(CRP) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-3(CRP) <2.6 = remission.

    Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24

  39. Percentage of Participants With Consecutive Visits of DAS28-4(ESR) <2.6 by Number of Consecutive Visits

    DAS28-4(ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and patient's global assessment of disease activity (participant rated arthritis activity assessment). Total score range: 0 to approximately 10, higher score=more disease activity. DAS28-4(ESR) ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate disease activity, >5.1 implied high disease activity, and DAS28-4(ESR) <2.6 = remission.

    Measured: Months 3, 6, 9, 12, 15, 18, 21, and 24

  40. Health Assessment Questionnaire Disability Index (HAQ-DI)

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  41. Change From Baseline in HAQ-DI Score

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  42. Percentage of Participants With at Least 0.22 Improvement in HAQ-DI Score

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  43. Percentage of Participants With at Least 0.3 Improvement in HAQ-DI Score

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  44. Percentage of Participants With at Least 0.5 Improvement in HAQ-DI

    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, hygiene, common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  45. Short Form 36 (SF-36) Mental Component Score

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  46. SF-36 Physical Component Score

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  47. Change From Baseline in SF-36 Mental Component Score

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  48. Change From Baseline in SF-36 Physical Component Score

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  49. SF-36 Domain Scores

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  50. Change From Baseline in SF-36 Domain Scores

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  51. Work Limitation Questionnaire (WLQ) Score

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time).

    Measured: Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  52. Change From Baseline in WLQ Scores

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time).

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  53. WLQ Work Loss Index Score

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0 [no loss] to 100 [complete loss of work]).

    Measured: Baseline and Months 3, 6, and 12

  54. Change From Baseline in WLQ Work Loss Index Score

    WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0 [no loss] to 100 [complete loss of work]).

    Measured: Months 3, 6, 12, 15, 18, 21, and 24

  55. European Quality of Life (EuroQol) Five Dimensions (EQ-5D) Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline and Months 3, 6, 12, 18, and 24

  56. Change From Baseline in EQ-5D Health State Profile Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Months 3, 6, 12, 18, and 24

  57. Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline and Months 3 and 6

    Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.

    Measured: Baseline and Months 3 and 6

  58. Work Productivity and Healthcare Resource Utilization (HCRU) at Months 12, 18, and 24

    RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.

    Measured: Months 12, 18, and 24

  59. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline and Months 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Baseline and Months 3 and 6

  60. Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Months 12, 18, and 24

  61. Number of Days as Assessed Using RA-HCRU at Baseline and Months 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Baseline and Months 3 and 6

  62. Number of Days as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Months 12, 18, and 24

  63. Number of Hours Per Day as Assessed Using RA-HCRU at Baseline and Months 3 and 6

    RA-HCRU assessed healthcare (HC) usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done, and work missed were reported.

    Measured: Baseline and Months 3 and 6

  64. Number of Hours Per Day as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done, and work missed were reported.

    Measured: Months 12, 18, and 24

  65. Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Baseline, Months 3, 6, 12, 18, and 24

  66. Change From Baseline in Work Productivity and HCRU at Months 3 and 6

    RA-HCRU assessed HC usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.

    Measured: Months 3 and 6

  67. Change From Baseline in Work Productivity and HCRU at Months 12, 18, and 24

    RA-HCRU assessed HC usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, non-medical practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, overnight stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score=higher medical cost.

    Measured: Months 12, 18, and 24

  68. Change From Baseline in Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 3 and 6

    RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Months 3 and 6

  69. Change From Baseline in Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.

    Measured: Months 12, 18, and 24

  70. Change From Baseline in Number of Days as Assessed Using RA-HCRU at Months 3 and 6

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Months 3 and 6

  71. Change From Baseline in Number of Days as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.

    Measured: Months 12, 18, and 24

  72. Change From Baseline in Number of Hours Per Day as Assessed Using RA-HCRU at Months 3 and 6

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home HC services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Months 3 and 6

  73. Change From Baseline in Number of Hours Per Day as Assessed Using RA-HCRU at Months 12, 18, and 24

    RA-HCRU assessed HC usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home HC services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.

    Measured: Months 12, 18, and 24

  74. Change From Baseline in Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU

    Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.

    Measured: Months 3, 6, 12, 18, and 24

  75. Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline and Months 1, 2, and 3

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.

    Measured: Baseline and Months 1, 2, and 3

  76. Percentage of Participants With Optimal Sleep Assessed Using MOS-SS

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported

    Measured: Months 1, 2, 3, 6, 12, 18, and 24

  77. Medical Outcomes Study Sleep Scale (MOS-SS) at Months 6, 12, 18, and 24

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.

    Measured: Months 6, 12, 18, and 24

  78. Change From Baseline in MOS-SS at Months 1, 2, and 3

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.

    Measured: Months 1, 2, and 3

  79. Change From Baseline in MOS-SS at Months 6, 12, 18, and 24

    Participant-rated 12 item questionnaire to assess constructs of sleep over past week. 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes or no). 9-item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher cores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range: 0-100, higher score=more intensity of attribute.

    Measured: Months 6, 12, 18, and 24

  80. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status

    Measured: Baseline and Months 1, 2, 3, 6, 12, 18, and 24

  81. Change From Baseline in FACIT-Fatigue Scale

    FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status

    Measured: Months 1, 2, 3, 6, 12, 18, and 24

  82. Change From Baseline in Heart Rate

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

  83. Change From Baseline in Temperature

    Measured: Months 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Dec 2009 (estimated)
  2. Study startJan 2010
  3. Primary completionMar 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
956 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01039688
Sponsor's protocol ID
A3921069
Other IDs
2009-016987-34, 2009
Acronym
ORAL1069
Status last verified
Mar 2018
First submitted
23 Dec 2009
Last updated
6 Apr 2018
Data monitoring committee
Yes

Publications

  • Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.

    PubMed 42888330
  • Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.

    PubMed 39192350
  • Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.

    PubMed 38958913
  • Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.

    PubMed 38883150
  • Ciurea A, Distler O, Kwok K, Jo H, Wang L, Killeen T, Ospelt C, Frank Bertoncelj M. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Res Ther. 2023 Sep 29;25(1):185. doi: 10.1186/s13075-023-03144-1.

    PubMed 37773189
  • Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.

    PubMed 37453736
  • Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

    PubMed 36931693
  • Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.

    PubMed 36814062
  • Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.

    PubMed 36601090
  • Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.

    PubMed 36600185
  • Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.

    PubMed 36526796
  • Dikranian AH, Gonzalez-Gay MA, Wellborne F, Alvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103.

    PubMed 35577477
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

    PubMed 34870800
  • Bykerk VP, Lee EB, van Vollenhoven R, Gruben DC, Fallon L, Woolcott JC, Keystone E. Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months. Arthritis Care Res (Hoboken). 2022 Jan;74(1):131-141. doi: 10.1002/acr.24709.

    PubMed 34057820
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.

    PubMed 33127856

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CP-690,550 and Disease-modifying antirheumatic drug in people with Arthritis, Rheumatoid, run by Pfizer at 176 sites in 30 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 176 sites in United States, Russia, Canada, Germany, India and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Apr 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Modified Total Sharp Score (mTSS) at Month 6 (time frame: Month 6). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01039688, which also lists 26 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in